LACTOLOGY FOUNDATION

Lansoprazole (ATC A02BC03) is a proton pump inhibitor used short‑term for acid‑related disorders, with generally low systemic toxicity but non‑negligible long‑term risks; during breastfeeding it is usually considered compatible with caution, though omeprazole or pantoprazole are preferred alternatives.file+5

Pharmacology and clinical use

Lansoprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversible inhibition of the H+^++/K+^++-ATPase in gastric parietal cells.drugbank+2
It is indicated for peptic ulcer disease, gastro‑oesophageal reflux disease (GERD), Helicobacter pylori eradication (as part of triple therapy), NSAID‑induced ulcers, and hypersecretory states such as Zollinger–Ellison syndrome.wikipedia+2
ATC classification places lansoprazole in A02BC03, within the proton pump inhibitor subgroup A02BC; the defined daily dose for oral administration is 30 mg.atcddd.fhi+2

Oral bioavailability is high, with about 80% of the dose rapidly absorbed from the gastrointestinal tract, and protein binding is around 97%.sciencedirect+2
Plasma half‑life in adults is short (approximately 1.3–1.7 hours), but the pharmacodynamic effect on acid suppression persists for more than 24 hours due to irreversible enzyme binding.file+2
Metabolism is hepatic via cytochrome P450 isoenzymes (mainly CYP2C19 and CYP3A4), with substantial interindividual variability and potential for clinically significant drug–drug interactions.drugbank+2

Toxicology and safety profile

Acute toxicity studies suggest relatively high minimal lethal doses in animal models, consistent with low acute toxicity at therapeutic exposures in humans.accessdata.fda
Common adverse effects are gastrointestinal (abdominal pain, constipation, diarrhea, nausea) and neurological (headache, dizziness), while serious reactions include Clostridioides difficile‑associated diarrhea, hypomagnesemia, interstitial nephritis, vitamin B12 deficiency, and increased fracture risk with prolonged use.sciencedirect+3
Hypergastrinemia and possible enterochromaffin‑like cell changes have raised concerns about long‑term carcinogenic potential; animal data show carcinogenicity, so prolonged or unnecessary therapy should be avoided, especially in vulnerable populations.wikipedia+3

Clinically, lansoprazole should generally not be used continuously beyond 8 weeks without reassessment, and special caution is required in patients with hepatic impairment or in those receiving long‑term therapy over 12 months due to risks of MALT lymphoma and osteoporotic fractures.file+3
In children, prolonged use may be associated with vitamin B12 deficiency and increased susceptibility to respiratory infections, particularly in poor CYP2C19 metabolizers.sciencedirect+2
Hypomagnesemia may potentiate digitalis toxicity and increase arrhythmia risk, underscoring the need for electrolyte monitoring during long‑term treatment.drugbank+2

Drug interactions

Due to extensive CYP450 metabolism, lansoprazole can increase plasma concentrations and/or effects of drugs such as diazepam, phenytoin, ciclosporin, tacrolimus, some antifungals, certain antiretrovirals, digoxin, and novel oral anticoagulants.file+2
Conversely, lansoprazole can reduce absorption and efficacy of drugs requiring an acidic gastric environment, including ketoconazole, itraconazole, some antibiotics (e.g. ampicillin), iron preparations, and mycophenolate mofetil.drugbank+2
Interactions at hepatic level may diminish therapeutic response to atazanavir, nelfinavir, rifampin and potentially clopidogrel, requiring careful evaluation of benefit–risk in patients receiving these agents.sciencedirect+2

Co‑administration with certain tyrosine kinase inhibitors (e.g. bosutinib) has been shown to significantly reduce peak plasma concentrations and AUC of the anticancer drug, illustrating the broader impact of gastric pH modification on orally administered agents.sciencedirect
Lansoprazole’s high protein binding could lead to displacement interactions, although these are usually less clinically significant than CYP‑mediated effects.file+1
Clinicians should routinely review concomitant medication before initiating lansoprazole, especially in polypharmacy, transplant, oncology, or cardiology patients.drugbank+2

Reproductive and lactation toxicology

In pregnancy, lansoprazole is classified as FDA category B, indicating absence of clear evidence of harm in animal studies but limited controlled human data.wikipedia+1
Clinical guidance often favors omeprazole in pregnancy because of its more extensive safety data, but lansoprazole can be used when the expected maternal benefit outweighs theoretical fetal risks.nhs+1
In lactation, pharmacokinetic characteristics—molecular weight around 369 Da and very high plasma protein binding—predict some passage into breast milk, but the quantity is likely small.e-lactation+2

Authoritative lactation resources consider lansoprazole probably compatible with breastfeeding, with excretion into human milk thought to be non‑significant and any small amount likely inactivated by the infant’s gastric acidity.sps+1
Regulatory and clinical guidance (e.g. NHS, specialist pharmacy services) recommend that lansoprazole may be used with caution in breastfeeding, but prefer omeprazole or pantoprazole because they have better evidence and documented minimal milk transfer.nhs+2
Despite these positions, the carcinogenic signal in animal studies and potential for acid suppression in the infant stomach justify a conservative approach; some lactology experts regard lansoprazole as unsuitable during lactation and categorize it as non‑compatible.e-lactation+2

Thus, from a toxicological‑lactological perspective, short‑term lansoprazole may be acceptable in breastfeeding when no safer alternative is feasible, but individual risk assessment, shared decision‑making, and preference for PPIs with more robust lactation data (omeprazole, pantoprazole) are advisable.sps+2
Monitoring of the breastfed infant for feeding difficulties, gastrointestinal symptoms or unusual irritability is recommended if the mother receives lansoprazole.nhs+2
Where maternal therapy can be switched without loss of efficacy, choosing a PPI with very low milk transfer is consistent with a precautionary, low‑toxic approach to breastfeeding pharmacotherapy.sps+2